257 related articles for article (PubMed ID: 19138988)
1. Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression.
Li X; Galipeau PC; Sanchez CA; Blount PL; Maley CC; Arnaudo J; Peiffer DA; Pokholok D; Gunderson KL; Reid BJ
Cancer Prev Res (Phila); 2008 Nov; 1(6):413-23. PubMed ID: 19138988
[TBL] [Abstract][Full Text] [Related]
2. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
[TBL] [Abstract][Full Text] [Related]
3. Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma.
Paulson TG; Maley CC; Li X; Li H; Sanchez CA; Chao DL; Odze RD; Vaughan TL; Blount PL; Reid BJ
Clin Cancer Res; 2009 May; 15(10):3305-14. PubMed ID: 19417022
[TBL] [Abstract][Full Text] [Related]
4. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
Galipeau PC; Li X; Blount PL; Maley CC; Sanchez CA; Odze RD; Ayub K; Rabinovitch PS; Vaughan TL; Reid BJ
PLoS Med; 2007 Feb; 4(2):e67. PubMed ID: 17326708
[TBL] [Abstract][Full Text] [Related]
5. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
[TBL] [Abstract][Full Text] [Related]
6. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.
Akagi T; Ito T; Kato M; Jin Z; Cheng Y; Kan T; Yamamoto G; Olaru A; Kawamata N; Boult J; Soukiasian HJ; Miller CW; Ogawa S; Meltzer SJ; Koeffler HP
Int J Cancer; 2009 Nov; 125(10):2349-59. PubMed ID: 19670330
[TBL] [Abstract][Full Text] [Related]
7. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
[TBL] [Abstract][Full Text] [Related]
8. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.
Rudolph RE; Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
J Natl Cancer Inst; 2003 May; 95(10):750-7. PubMed ID: 12759393
[TBL] [Abstract][Full Text] [Related]
9. Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus.
Li X; Galipeau PC; Paulson TG; Sanchez CA; Arnaudo J; Liu K; Sather CL; Kostadinov RL; Odze RD; Kuhner MK; Maley CC; Self SG; Vaughan TL; Blount PL; Reid BJ
Cancer Prev Res (Phila); 2014 Jan; 7(1):114-27. PubMed ID: 24253313
[TBL] [Abstract][Full Text] [Related]
10. Losses of heterozygosity on chromosomes 9p and 17p are frequent events in Barrett's metaplasia not associated with dysplasia or adenocarcinoma.
Suspiro A; Pereira AD; Afonso A; Albuquerque C; Chaves P; Soares J; Leitão CN
Am J Gastroenterol; 2003 Apr; 98(4):728-34. PubMed ID: 12738448
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus.
Dolan K; Morris AI; Gosney JR; Field JK; Sutton R
J Gastroenterol Hepatol; 2003 Jun; 18(6):683-9. PubMed ID: 12753151
[TBL] [Abstract][Full Text] [Related]
12. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
[TBL] [Abstract][Full Text] [Related]
13. Deletion at fragile sites is a common and early event in Barrett's esophagus.
Lai LA; Kostadinov R; Barrett MT; Peiffer DA; Pokholok D; Odze R; Sanchez CA; Maley CC; Reid BJ; Gunderson KL; Rabinovitch PS
Mol Cancer Res; 2010 Aug; 8(8):1084-94. PubMed ID: 20647332
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays.
Wiech T; Nikolopoulos E; Weis R; Langer R; Bartholomé K; Timmer J; Walch AK; Höfler H; Werner M
Lab Invest; 2009 Apr; 89(4):385-97. PubMed ID: 18663352
[TBL] [Abstract][Full Text] [Related]
15. Massively Parallel Sequencing of Esophageal Brushings Enables an Aneuploidy-Based Classification of Patients With Barrett's Esophagus.
Douville C; Moinova HR; Thota PN; Shaheen NJ; Iyer PG; Canto MI; Wang JS; Dumot JA; Faulx A; Kinzler KW; Papadopoulos N; Vogelstein B; Markowitz SD; Bettegowda C; Willis JE; Chak A
Gastroenterology; 2021 May; 160(6):2043-2054.e2. PubMed ID: 33493502
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis.
Gu J; Ajani JA; Hawk ET; Ye Y; Lee JH; Bhutani MS; Hofstetter WL; Swisher SG; Wang KK; Wu X
Cancer Prev Res (Phila); 2010 Sep; 3(9):1176-86. PubMed ID: 20651033
[TBL] [Abstract][Full Text] [Related]
17. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
Sanz-Ortega J; Hernández S; Saez MC; Sierra E; Sanz-Ortega G; Torres A; Balibrea JL; Sanz-Esponera J; Merino MJ
Hepatogastroenterology; 2003; 50(50):404-7. PubMed ID: 12749233
[TBL] [Abstract][Full Text] [Related]
18. Evolution of neoplastic cell lineages in Barrett oesophagus.
Barrett MT; Sanchez CA; Prevo LJ; Wong DJ; Galipeau PC; Paulson TG; Rabinovitch PS; Reid BJ
Nat Genet; 1999 May; 22(1):106-9. PubMed ID: 10319873
[TBL] [Abstract][Full Text] [Related]
19. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation.
Wongsurawat VJ; Finley JC; Galipeau PC; Sanchez CA; Maley CC; Li X; Blount PL; Odze RD; Rabinovitch PS; Reid BJ
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):509-16. PubMed ID: 16537709
[TBL] [Abstract][Full Text] [Related]
20. Re: clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
Walch A; Mueller J; Höfler H; Werner M
J Natl Cancer Inst; 2000 Jul; 92(14):1182-3. PubMed ID: 10904093
[No Abstract] [Full Text] [Related]
[Next] [New Search]
